HomepageRCT BackgroundOur ServicesLaboratoryStaffStudy VolunteersStudies and PublicationsContact us
 
Studies Performed by Respiratory Clinical Trials Ltd or by **Nephro-Urology Clinical Trials Ltd

  Ex Vivo Studies

In vitro assessment of the activity of RBX 7796 using whole human blood flow cytometry; Effects on neutrophil and eosinophil shape (chemotaxis) and CD11b up regulation

Assessment of XXX using Whole Human Blood Flow Cytometry : Effects in vitro on Eotaxin-induced Eosinophil Shape Change (Chemotaxis) and CD11b Upregulation

Assessment of the effects of SYN-XXX on the secretion of PTH by primary bovine parathyroid cell cultures (monolayer and pseudogland)

Phase 1 - Volunteer studies

1. **A single-blind, 4-way crossover study, to compare the effects of two different doses of ABT 980 (10 & 30mg) or Tamsulosin (0.4mg) with placebo on systemic blood pressure and intra urethral pressure following phenylephrine   Completed
12 normal volunteers
2. **Phase I, open-label, single-center, randomized, four-period complete crossover study to investigate the effects of single doses of RBX-2258 (1 and 2 mg), tamsulosin (0.4 mg), and placebo on phenylephrine (PE)-induced increases in prostatic pressure and blood pressure   Completed
12 normal volunteers
3. **Phase I, open-label, single-center, randomized, four-period complete crossover study to investigate the effects of single doses of RWJ 38063 PHI-013 (20 and 40 mg), tamsulosin (0.4 mg), and placebo on phenylephrine (PE)-induced increases in prostatic pressure and blood pressure   Completed
12 normal volunteers
4. **A single-blind, 3-way crossover study, to compare the effects of terazosin (5mg) or indoramin (2mg) with placebo on systemic blood pressure and intra urethral pressure following phenylephrine infusions
  Completed
16 normal volunteers
5. **Phase I, single blind, placebo controlled, escalating single dose, 4-way crossover study to investigate the safety, toleration and pharmacokinetics of intravenous UK-224, 671
  Completed
16 normal volunteers
6. **Phase I, single blind, placebo controlled, escalating single dose, 4-way crossover study to investigate the safety, toleration and pharmacokinetics of intravenous UK-224, 671   Completed
16 normal volunteers
7. **A pilot methodology study to determine the ejaculatory latency time in normal healthy subjects using the PE diagnostic device and video sexual stimulation
  Completed
16 normal volunteers
8. **Phase I, double blind, placebo controlled, randomised four-way cross over study to investigate the safety, tolerability and pharmacokinetics of Physostigmine oral spray in healthy male volunteers
  Completed
16 normal volunteers
9. **A double-blind, double dummy, randomised, three way cross-over study to investigate the pharmacokinetics and pharmacodynamics of single oral doses of RWJ-387273, sildenafil or placebo in healthy male volunteers
  Completed
16 normal volunteers
10. **A clinical study in healthy normal volunteers to validate the methodologies of Laser Doppler Flowmetry (LDF) and transabdominal Doppler for the measurement of colorectal mucosal perfusion and small intestinal blood flow
  Completed
24 normal female volunteers
11. A pilot study to determine the effect of tegaserod on mucosal blood flow determined by laser Doppler Flowmetry in patients with idiopathic slow transit constipation   Completed
8 female patients
12. Study in Healthy Volunteers to Investigate the Effect of Oral Dosing with AZD8309 on Airway Inflammation as Assessed in Induced Sputum after Challenge with Inhaled Lipopolysaccharide (LPS)
  Completed
20 healthy participants
13. **Phase I, double blind, placebo controlled, randomised, four way cross over, single ascending dose study to investigate the safety, tolerability and pharmacokinetics of VR776 administered via Aspirair inhaler in healthy male volunteers.
  Completed
13 healthy participants

Phase 2a / Phase 2b Studies
14. **A double-blind, 2-way crossover pilot study, to compare the effects of topical phenylephrine gel with placebo on systemic blood pressure and intra-urethral pressure in patients with stress incontinence
  Completed
n=12 patients with stress incontinence
15. **An Open-label Study of Prostate Size and Appearance in Benign Prostatic Hyperplasia Patients Treated with Terazosin   Completed
n=12 patients with BPH
16. **A randomized double-blind, double dummy, placebo-controlled, three way Cross-Over Study To Compare the Effect of a single Oral dose of R216073 or Placebo with single oral dose of Oxybutynin on Unstable Detrusor Contractions Induced By Volume Provocation In Patients With Detrusor Hyper-Reflexia Secondary To Spinal Injury.
  Completed
n=8 pts with spinal injury
17. **A double blind, cross-over study to compare the effect of intravenous darifenacin with placebo on unstable contractions induced by provocation in patients with detrusor hyperreflexia secondary to spinal injury.
  Completed
n=8 pts with spinal injury
18. An Exploratory Study to Evaluate the Single-dose Pharmacokinetics and Hemoglobin Response After Multiple doses of Darbepoetin Alfa in Subjects with Chronic Obstructive Pulmonary Disease (COPD) and Anemia
  Completed
n=8 patients with COPD
19. A placebo-controlled, double-blind, two-way crossover study of the effects of 14 days of inhalation treatment with AVE0309 on allergen induced bronchoconstriction in male and female patients with atopic asthma
  Completed
n=24 patients with asthma
20. A Double Blind Randomized Five-Way Crossover, Placebo-Controlled Study to Assess the Efficacy of Three Doses (250 mg-500 mg and 1000mg bid) at steady state, of CDP323 on Eosinophils Trafficking after a Nasal Allergen Challenge in Seasonal Allergic Patients
  Completed
n=16 patients with allergic rhinitis
21. A multi-centre, randomised, double-blind, placebo controlled, crossover study to examine the efficacy, safety, tolerability and systemic pharmacokinetics profile of single inhaled dose of GW597901X in asthmatic subjects   Completed
n=16 patients with mild asthma
22. A Double-blind, Placebo-controlled, Randomised Two-way Cross-over Study to Evaluate the Effects of KW-4490 on Early and Late Asthmatic Reactions (EAR and LAR), Airway Methacholine Reactivity, and Breath and Sputum Inflammatory Indices following Inhaled Allergen Challenge in Subjects with Mild Allergic Asthma
  Completed
n=24 patients with mild asthma
23. A double blind placebo controlled two way cross –over study to determine the effects of a single dose of topical steroid on eosinophils and levels of chemokines and cytokines in nasal lavage fluid following nasal allergen challenge in patients with allergic rhinitis
  Completed
n=16 patients with allergic rhinitis
24. A double blind placebo controlled four- way cross-over study to determine the effects of two doses of RWJ-58643 on nasal symptoms, eosinophil influx and cytokine and chemokine release following nasal allergen challenge.
  Completed
n=16 patients with allergic rhinitis
25. A randomized, double-blind, placebo-controlled, parallel group pilot study to determine the effect of Remicadeâ on safety, efficacy and biomarkers of inflammation in patients with asthma receiving inhaled corticosteriods: a pilot study to investigate the effect of tnf a-directed therapy in asthma
  Completed
50 patients with mild to moderate asthma
26. Randomized, double blind, two centers, placebo controlled, 4-way cross-over exercise-induced bronchoconstriction trial after multiple oral dose (62.5 mg, 125 mg and 312.5 mg expressed as base) of UCB-35440-3 in male subjects with mild asthma with a known exercise-induced bronchoconstriction (EIB).
  Completed
24 patients with mild asthma
27. A study to determine the value of Multi-Slice Computed Tomography for the non-invasive detection of coronary artery calcification in asymptomatic individuals and patients with mild symptoms of coronary artery disease
  Completed
50 patients with coronary artery disease
28. A Randomised, Double Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effect of Regadenoson on Pulmonary Function in AMP-Sensitive Subjects with Mild or Moderate Asthma
  Completed
24 Mild Asthmatics & 24 Moderate Asthmatics
29. A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover A Randomised, Single-Blind, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses Of CVT-6883 in Adults with Mild and Moderate Asthma
  Completed
18 Mild Asthmatics
30. A double-blind, placebo-controlled, randomised, 4-way crossover single dose escalation and a double-blind, placebo-controlled, randomised, parallel group, 7-days repeat once daily dose study to investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW870086X administered via DISKHALER in healthy male subjects followed by a double-blind, placebo-controlled, 3-way crossover study to investigate the effect of 7-days repeat once daily inhaled doses of GW870086X administered via DISKHALER on airway responsiveness to AMP in mild steroid-naïve male asthmatics
  Completed
20 Mild/Moderate Asthmatics
31. **Phase II double-blind, intermittent dose, placebo-controlled, randomised, 2 period crossover study to investigate the effect of inhaled doses of VR776 administered via Aspirair inhaler on time to ejaculation measured by stop watch in male patients with premature ejaculation
  Completed
40 patients with Premature Ejaculation
32. **A Randomised, Placebo-Controlled, Crossover study to Measure the effect of Alosetron on Mucosal Blood Flow in Female Healthy Volunteers and Diarrhoea-Predominant IBS Subjects
  Completed
22 Healthy Participants
Active
22 D-IBS Participants
33. **An Open-label, escalating dose, proof of concept study to determine the effect of single dose oral PSD506 on unstable urinary bladder contractions induced by volume provocation in subjects with hyper-reflexia secondary to spinal injuries above T12
  Completed
16 Participants with spinal injuries above T12
34. A randomised, double blind, single centre, crossover study to compare the effects on cortisol secretion of the combination FP/SM-HFA delivered by pressurised metered dose inhaler (pMDI) with FP-HFA pMDI and SM-CFC pMDI, given concurrently for 1 week in healthy volunteers
  Completed
20 healthy volunteers
35. A single dose, double blind, double dummy, 3 period cross-over, placebo controlled clinical trial to assess the rate of onset of action of inhaled LAS 34273 200mcg compared to placebo and tiotropium 18mcg in patients with chronic obstructive pulmonary disease (COPD)
  Completed
12 Participants with Severe COPD
36. An investigation to evaluate the technique of MRI as an assessment of the effect of anti-allergy drug treatment on internal nasal and sinus mucosal anatomy following intranasal allergen challenge in subjects with seasonal allergic rhinitis.
  Completed
21 Patients Seasonal Allergic Rhinitis
37. A Pilot Methodology Study to Investigate Biomarker Activity in the Sputum of Healthy Volunteers Following Challenge with Inhaled Lipopolysaccharide (LPS)
  Completed
20 healthy participants
38. A single-blind, two-way crossover pilot study, to validate the measurement of intra-urethral pressure using a novel solid-state catheter in normal female volunteers.
  Active
12 healthy participants
39. Pilot Study in normal volunteers to validate sputum methodology as assessed in induced sputum after challenge with inhaled LPS   Completed
12 healthy participants
40. Randomised double blind placebo controlled 2 way Cross-Over Study in healthy volunteers to investigate the Effect of oral AZD9668 on airway inflammation as assessed in induced sputum after challenge with inhaled LPS
  Completed
16 healthy participants
41. Dose response evaluation of CHF 1535 HFA pMDI in asthmatic patients using lung function, adenosine monophosphate bronchial challenge and fractional exhaled nitric oxide (FEno). A randomized, double blind, double dummy, placebo controlled, multiple dose, 3 way cross over design.
  Completed
24 patients with asthma
42. A placebo controlled single blind phase 2 study to evaluate the safety and efficacy of KB002 a chimeric monoclonal antibody on eosinophil influx & markers of inflammation following intranasal allergen challenge in subjects with seasonal allergic rhinitis
  Completed
16 patients with allergic rhinitis
43. A placebo controlled single blind phase 2 study to evaluate the safety and efficacy of KB002 a chimeric monoclonal antibody on neutrophil influx & markers of inflammation following intranasal lipopolysaccharide challenge in normal subjects
  Completed
16 Healthy volunteers
44. A double-blind, placebo-controlled, parallel study to evaluate the effects of GW856553 on endothelial function/vascular compliance in subjects with dyslipidemia
  Completed
20 patients with ischemic heart disease.
45. A double blind placebo controlled study to evaluate the effects of two regimens of GW856553 over a period of three months on an in vivo macrophage activity as assessed by FDG-PET CT imaging in the carotid arteries and aorta in patients with established atherosclerosis
  In Progress
n=200 patients with atherosclerosis

46. A randomized, multi-centre, parallel group, double blind, placebo and formoterol controlled 14 day dose ranging trial of 4 doses of indacterol delivered via Twisthaler® in adult and adolescent patients with persistent asthma
  Completed
n=24 patients (170 study total) with moderate asthma
47. A Pilot Methodology Study to Investigate Biomarker Activity in the Sputum of Healthy Volunteers Following Challenge with Inhaled Lipopolysaccharide (LPS)   Completed
12 normal subjects
48. A two-center, double-blind, placebo-controlled, randomized, 2-period cross-over, Phase IIa study to investigate the pharmacodynamics, tolerability and safety, and pharmacokinetics of ACT129968 in subjects with mild to moderate allergic asthma
  In Progress
n=20 smokers; n=20 normal subjects n=60 COPDpts
49. A 2-Center, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of 600 mg MEM 1414 in the Human Allergen Challenge Model.
  In Progress
n=18 mild asthma pts
50. A randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with GSK2190915 on the allergen-induced asthmatic response in subjects with mild asthma   In Progress
n=16 mild asthma patients
51. A randomised, double-blind, placebo-controlled, 3-period cross-over study to evaluate the effect of 2 doses of GSK2190915 on the allergen-induced early asthmatic response in subjects with mild asthma
  In Progress
n= 36 mild asthmatics
52. A Randomized Clinical Trial to Study the Effects of Single Dose of Corticosteroid on Response to Nasal Allergen Challenge in Patients
  In Progress
n=12 healthy participants
53. **A pilot study to evaluate a novel wearable conditional neuromodulator for treating urinary incontinence in spinal cord injury
Completed n=8 spinal injury patients
  Completed
n=8 spinal injury patients
54. A single dose randomised double blind double dummy placebo controlled three period cross-over study comparing the onset of relief from Methacholine induced broncho-constriction with fixed combination beclomethasone dipropionate 100ug plus formoterol fumarate 6ug/actuation pMDI with HFA-134a propellant (Foster) versus standard salbutamol pMDI 100ug/actuation (Ventolin) therapy in asthmatic patients
  In Progress
n=24 asthmatic patients
55. An exploratory, randomised, double blind, placebo controlled, 14 day, two-way crossover, inhaled allergen challenge study to evaluate the effects of XXX in subjects with mild to moderate asthma   In Progress
n=24 mild asthmatics
56. A double-blind, placebo controlled, randomised, parallel group, phase IIa study to investigate the efficacy, tolerability and safety of 8 doses of AZD8848 administered intranasally once weekly over 7 weeks in mild to moderate asthma patients challenged with an inhaled allergen
  In Progress
n= 50 mild asthmatics
57. An exploratory, randomised, double blind, placebo-controlled, 14 day, three-way crossover study, followed by an open label 1 day period when subjects will be dosed with intranasal fluticasone, nasal allergen challenge (NAC) study to evaluate the effects of XXX on the release of inflammatory mediators after NAC with Timothy grass pollen in subjects with allergic rhinitis out of season
  In Progress
n=50 allergic rhinitis patients
58. **A randomised, double-blind, active-controlled, 3-way Cross-over study to evaluate the effect on trough FEV1. After 4 weeks treatment with chf 5188 pmdi (400/4µg qd)
(fixed combination budesonide / carmoterol 200/2µg) in adult
Patients with moderate or severe persistent asthma
  In Progress
n=50 asthmatic patients


 
Recent Publications

 
Single dose topical corticosteroid inhibits IL-5 & IL-13 in nasal lavage
following grass pollen challenge

E M. Erin, B Leaker , LA Higgins, MJ Boyce, P de Boer, SR Durham, P J. Barnes, T.T.Hansel

  Allergy 60:1524-9 2005
Effects of a reversible β-tryptase and trypsin inhibitor (RWJ-58643) on
nasal allergic responses:.

E M. Erin, B Leaker , P de Boer, RC Jones, SR Durham P J. Barnes, T.T.Hansel
  Clinical & Exp Allergy 36, 458-464 2006
The effects of a Monoclonal Antibody directed against Tumour necrosis factor alpha in asthma
E M. Erin, B Leaker , A Tan, GC Nicolson, LM Green, H Neighbour, ES, Barnathan, OM Kon , P J. Barnes T.T.Hansel
  Am J Respir Crit Care 174:753-62, 2006
Pharmacologic modulation of gut mucosal and large vessel blood flow
MA Kamm, CC Jordan, BR Leaker, FB Nicholson, CDR Murray, S Taylor, M Marshall, A Gibbs, EG Carter, AV Emmanuel
  Alimentary Pharmacology and therapeutics 25:693-702, 2007
Safety of regadenoson, an A2A receptor agonist for myocardial perfusion imaging in Asthmatic patients : a randomised double blind placebo controlled trial.
BR Leaker, B O’Connor, TT Hansel, PJ Barnes, L Meng, VS Mathur, HD Lieu

  J Nuc Cardiol 15 (3) 329-336 2008
(Epub 2008 Apr 14th)
Optimised dialysis and protease inhibition of sputum dithiothreitol supernatants
E M. Erin, Jenkins GR, OM Kon, AS Zacharasiewicz , GC Nicolson, H Neighbour, RC Tennant, A Tan, B Leaker A Bush, PJ Jose LM Green, P J. Barnes T.T.Hansel

  Am J Respir Crit Care, 177 (2) 132-141 2008 (ePUB 2007 Oct 25)



Abstracts and International Presentations
*Alpha1 -Adrenoceptor antagonist selectivity determined by simultaneous blood pressure and long-term urethral pressure monitoring in men.
Sultana S, Murray K , Craggs M ,Wyllie M , Leaker B

*winner of Glaxo-Welcome prize for clinical pharmacology
  Br J Pharmacol 1998 45; 191P
Ischaemic reperfusion injury to the kidney; A post injury perspective on the treatment of with Endothelin receptor antagonists in the rat
Jones C, Leaker B, Becker GJ.
  Kid Int (suppl1) 1997
A comparison of Doxazosin and Tamsulosin on mean arterial blood pressure ; attenuation of phenylephrine induced pressor responses in normotensive volunteers
Sultana S, Wyllie M, Leaker B
  Eur J Urol 1998 33 (suppl 1) ; 128
Determining alpha blocker selectivity; simultaneous blood pressure and urethral pressure measurement.
Sultana S, Murray K, Craggs, M, Leaker B
  J Urol Suppl 1997; 157:315
A study to assess the effect of Darifenacin on unstable contractions in spinal injury patients
B Leaker, J Bycroft, S Knight, PR Shah, MD Craggs
  ICS Proceedings 2003, 33rd annual meeting p47-48
A study to assess the effect of Darifenacin on provoked unstable contractions in spinal cord injury patients
B Leaker, J Bycroft, S Knight, PR Shah, MD Craggs
  ISCoS Proceedings 2003, 42nd Annual meeting
Evaluation of the relationship between constipating medication and gut mucosal and large vessel blood flow
Emmanuel AV, Nicholson FB, Murray CD, Taylor SA, Leaker BR, Jordan CC, Kamm MA.
  Gastroenterology; Suppl 128 (4) 2005
A reversible inhibitor of mast cell ß-tryptase and trypsin (RWJ-58643) causes inhibition of symptoms, eosinophils and IL-5 following nasal challenge with Timothy grass pollen.
EM Erin, BR Leaker , P de Boer, P J. Barnes TT.Hansel
Prize winning abstract; the American Thoracic Society 2004
  Am J Respiratory and Crit care 2004; 169:A859
The effects of a Monoclonal Antibody directed against Tumour necrosis factor alpha in Asthma.
E M. Erin, B Leaker, A Tan, GC Nicolson, LM Green, H Neighbour, ES Barnathan, OM Kon P J. Barnes T.T.Hansel
  Am J Respir Crit Care, 2006
Safety of regadenoson, an adenosine A2A receptor agonist in patients with Asthma: a randomised double blind controlled trial
BR Leaker, B O’Connor, A Olmstead, VS Mathur, HD Lieu
  ICNC May 2007
Safety of regadenoson, an A2A receptor agonist for myocardial perfusion imaging in Asthmatic patients : a randomised double blind placebo controlled trial.
BR Leaker, B O’Connor, TT Hansel, PJ Barnes, L Meng, VS Mathur, HD Lieu
  Am Soc Nuc Cardiol 2007
Lack of correlation between symptoms of dyspnoea and bronchospasm in Asthmatics receiving regadenoson: a randomised double blind placebo controlled trial
BR Leaker, B O’Connor, TT Hansel, PJ Barnes, L Weng, VS Mathur, HD Lieu
  Am J Respir and Crit care 2007
Results from two randomised , double blind clinical trials evaluating the safety of regadenoson in patients with reactive airways disease
G Thomas, BR Leaker, H Lieu, D Milliken, L Meng, V Marthur
  Eur Heart Journal 2007
Inhibition of neutrophilic inflammation in an inhaled LPS challenge model in healthy volunteers
BO’Connor, BR Leaker, C Grahames, N Bengt, N Snell, P Newbold
  Eur Resp J Vol 30, suppl 51 pp 209 2007
Optimised dialysis and protease inhibition of sputum dithiothreitol supernatants increases detectable levels of chemokines and cytokines in asthma
E M. Erin, B Leaker, A Tan, GC Nicolson, LM Green, H Neighbour, OM Kon P J. Barnes T.T.Hansel
  Am J Respir Crit Care, 2007
A double blind, placebo controlled, randomised cross-over study to investigate the effect of inhaled doses of VR776 on IVELT in patients with premature ejaculation
B Leaker, P Kell, M Main. D Ralph
  J Sex Med 5 (suppl 2) 45-68; 2008
The clinical assessment of nasal congestion with Magnetic Resonance Imaging; a randomised placebo controlled trial of cetrizine and pseudoephedrine
A Sousa, G Scadding, S Rossomanno, S Miller, B Leaker, R Marshall
 
Am J Respir Crit Care, 2009 (Abs)
Broncho-protective and anti-inflammatory effect of beclomethasone diproprionate plus formoterol HFA fixed combination in asthmatic patients fixed combination in asthmatic patients:Brian O’Connor2, Sara Collarini1, Gianluigi Poli1, Caterina Brindicci1, Daniela Acerbi1 Peter J Barnes2 and Brian Leaker2
1Chiesi Farmaceutici S.p.A., Parma, Italy; 2Respiratory Clinical Trials, London, UK
  European Respiratory Journal Vol 34 Suppl 53 pp 337s 2009
Conditional Neuromodulation using trans-rectal stimulation in spinal cord injury
Craggs M, Edirisinghe N, Leaker B, Susser J, Al-Mukhtar M, Donaldson N
Neurourol & Urodyn
  2009; 28(2): 836-837
Conditional Neuromodulation to Control Neurogenic Incontinence
M.D. Craggs, N.A. Edirisinghe, B. Leaker, J. Susser, S. Knight, N. Donaldson
  Clinical Neurophysiology 2009 (In press)
A novel wearable device for controlling urinary incontinence by conditional Neuromodulation
Edirisinghe N, Leaker B, Susser J, Al-Mukhtar M,Donaldson N, Craggs M
  Spinal Cord 2009 (In press)
A novel wearable conditional neuromodulator for treating urinary incontinence in spinal cord injury
N.A. Edirisinghe, J. Susser, M. Al-Mukhtar, S. Knight, B. Leaker, N. Donaldson, M.D. Craggs
  Proceedings of the UK Continence Society. Swansea, Wales, UK. April, 2009
Novel Wearable Conditional Stimulation Device For Continence Control
Edirisinghe N, Leaker B, Susser J, Al-mukhtar M, Donaldson N, Craggs M
  Assessment Of A Proceedings of the Annual Scientific Meeting of the Institute of Physics & Engineering in Medicine (IPEM) South East Group. Maidstone, Kent UK. May 2009
Conditional Neuromodulation to Control Neurogenic Incontinence
M.D. Craggs, N.A. Edirisinghe, B. Leaker, J. Susser, S. Knight, N. Donaldson
  Proceedings of a Scientific Meeting of the British Society of Clinical Neurophysiology. Poole, Dorset. UK. June, 2009
Conditional Neuromodulation using trans-rectal stimulation in spinal cord injury
Craggs M, Edirisinghe N, Leaker B, Susser J, Al-Mukhtar M, Donaldson N
 

Neurourol & Urodyn
2009; 28(2): 836-837
roceedings of the 39th Annual Meeting of the International Continence Society. San Francisco, US. September 2009

A novel wearable device for controlling urinary incontinence by conditional Neuromodulation
Craggs M, Edirisinghe N, Leaker B, Susser J, Al-Mukhtar M,Donaldson N.
  Proceedings of the 48th Annual Scientific Meeting of the International Spinal Cord Society. Florence, Italy. October 2009.
A novel wearable medical device for controlling urinary incontinence by conditional neuromodulation
Edirisinghe N, Leaker B, Susser J, Al-mukhtar M, Donaldson N, Craggs M
  Conference Proceedings of the Institute of Mechanical Engineers. London, UK. November, 2009)
A Two Center, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses of MEM 1414 (600 mg) on the Allergen-Induced Late Asthmatic Reaction in Steroid-Free Subjects
with Mild Allergic Asthma
B Leaker, D Singh, P Barnes, R Hughes M Imrie, B O’Connor A two center, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses of MEM 1414 (600 mg) on the Allergen-Induced Late Asthmatic Reaction in Steroid-Free Subjects with Mild Allergic Asthma.
  Am J Respir Crit Care Med 181;2010:A5613
Carayannopoulos LN, Ruddy MK, Leaker BR, Calder NA, Mogg R, Nicholson GC Imrie M, Chung H, Bolognese JA, De Lepeleire I, Swift G, Tan AJ, Tribouley C, Tokiwa GY, Hansel TT Effects of Single Doses of Oral Corticosteroid on Biomarkers of
Nasal Allergen Challenge (NAC)
  Am J Respir Crit Care Med 181;2010:A1402

   


Homepage    |    RCT Background   |   Our Services   |    Laboratory   |    Staff    |    Study Volunteers    |    Studies and Publications    |   Contact us